A Phase 2 clinical trial reveals that an ultrahypofractionated 5-day preoperative radiation regimen for high-risk soft tissue sarcoma provides durable local control and favorable late-term toxicity compared to the conventional 5-week course, potentially revolutionizing the standard of care for patient convenience.